Michael currently serves as Senior Manager of the Botin Foundation’s Science Department, an auspice of the Bank of Santander and the nation's largest philanthropy. The Foundation invests in early biomedical developments of promising life science discoveries across a range of technologies and therapeutic areas, through research collaborations with top academic investigators, startup creation, investment, and for-profit life science companies dedicated to accelerating developments of scientific discoveries into viable innovations to improve health, wellbeing, and geared towards socioeconomic impact. Prior to the Botin Foundation, Michael was manager at CrossRoadBiotech Venture Capital, and Head of Technology Transfer and Innovation and the National Cancer Research Centre of the Ministry of Health. Prior to graduate school, Michael worked at Microcell Solutions and the Hudson Bay Company as account manager and interim supervisor. Michael graduated from Concordia University in Montreal Canada with a Bachelor Degree in Specialization of Cellular and Molecular Biology and an Economics and Business Clusters. He received his Ph.D. from the Ministry of Technology’s National Biotechnology Centre at the University of Madrid with Honors Cum Lauden in Molecular Biology. Michael also holds degrees from the Lycee Francais Jean-Renoir in Munich, and the JFK Institute in Berlin, Germany. Michael is passionate about life sciences and in helping to better bridge the capabilities of the for-profit, nonprofit, and academic sectors to speed up development of more effective treatments.
Since April 2008
The Botin Foundation's Science Program aims to globally address national science and technology (S&T) issues, and particularly tackles issues in knowledge and technology transfer, technology development, by promoting the acceleration of translational research in biomedical biotechnology.
October 2007 --- April 2008
Cross Road Biotech is a venture capital management firm that invest in the development of seed stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses. To that end, the company selects innovative projects led by prestigious scientists and entrepreneurs, providing financing, management support and strategic advice. CRB Inverbío is based upon the expertise and successful track record in continuous value creation of Cross Road Biotech. CRB Inverbío has a unique competitive advantage: the expertise, analytical capabilities and commitment to succeed of the management team: a key element to build highly successful businesses and maximize the returns to the investors. CRB Inverbío manages Funds and Venture Capital Firms specialized in life sciences. At present the company is launching CRB Bio II, a 60M€ venture capital fund to invest in emerging companies for life sciences, an attractive opportunity to participate in one of the most powerful investment sector of the new economy.
Research Support - Head of Technology Transfer & Industry Liaison
October 2005 --- October 2007
Credit Associate & Interim Manager
September 2001 --- September 2002
January 1999 --- September 2000
Doctor of Philosophy (Ph.D.) in Molecular Biology from National Centre of Biotechnology - Ministry of Science and Technology - University of Madrid in 2005
Bachelors in Science (B.Sc.) & Economics & Business Clusters (E.B.C.) in Specialization - Cellular and Molecular Biology from Concordia University - Montreal, Canada in 2002
Diploma - Advance in Biology in biology from JFK - Berlin, Germany in 1997
Bacc. Francais in 1re Science from Lycee Francais Jean Renoir - Munich, Germany in 1996
College in Social Studies - Sociology from Champlain College in 1995